Skip to content

Study · Randomized controlled trial · n = 68 · 2023

5 results

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.

Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C

Diabetes, obesity & metabolism1 Jun 2023Cited by 47 (Europe PMC)

PMID37264711 (opens in a new tab)DOI10.1111/dom.15150 (opens in a new tab)PepBankPUB-37264711
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In people with type 2 diabetes receiving orforglipron, gastrointestinal events were the most common adverse events and occurred early.

    In plain wordsIn people with diabetes receiving orforglipron, digestive adverse events were most common and occurred early.

    Peptide
    Orforglipron
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n = 68

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were gastrointestinal-related, and occurred early in treatment, similar to findings with other GLP-1RAs.
    2 context sentences
    Summary · context
    Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 weeks.
    Summary · context
    Eligible participants with T2D were aged 18 to 70 years and had glycated haemoglobin (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes, HbA1c change ranged from -1.5% to -1.8% across orforglipron doses versus -0.4% with placebo.

    In plain wordsIn people with diabetes, orforglipron reduced HbA1c more than placebo.

    Peptide
    Orforglipron
    Outcome
    DecreaseHbA1c change
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.5 to −1.8%
    orforglipron
    HbA1c change
    −0.4%
    placebo

    Source sentences

    Summary
    Mean HbA1c change ranged from -1.5% to -1.8% across orforglipron doses, versus -0.4% with placebo,
    2 context sentences
    Summary · context
    Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 weeks.
    Summary · context
    Eligible participants with T2D were aged 18 to 70 years and had glycated haemoglobin (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes, weight change ranged from -0.24 to -5.8 kg across orforglipron doses versus 0.5 kg with placebo.

    In plain wordsIn people with diabetes, weight decreased with orforglipron and increased with placebo.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight change
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 weeksAs given in this study (human).

    Measurements

    Weight change
    −0.24 to −5.8 kg
    orforglipron
    Weight change
    0.5 kg
    placebo

    Source sentences

    Summary
    body weight change was -0.24 to -5.8 kg across orforglipron doses, versus 0.5 kg with placebo.
    2 context sentences
    Summary · context
    Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 weeks.
    Summary · context
    Eligible participants with T2D were aged 18 to 70 years and had glycated haemoglobin (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).
  4. 04HumanRandomized controlled trialSafety outcome

    In people with type 2 diabetes, weekly escalation of daily orforglipron doses was generally well tolerated in the first group.

    In plain wordsIn people with type 2 diabetes, the first group generally tolerated weekly increases in daily orforglipron doses.

    Peptide
    Orforglipron
    Outcome
    Not applicableDose escalation tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The first group established that weekly dose escalation of the daily doses of orforglipron was generally well tolerated.
    2 context sentences
    Summary · context
    Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 weeks.
    Summary · context
    Eligible participants with T2D were aged 18 to 70 years and had glycated haemoglobin (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).
  5. 05HumanRandomized controlled trialPharmacokinetics

    In people with type 2 diabetes, mean orforglipron half-life ranged from 29 to 49 hours at Week 12.

    In plain wordsIn people with diabetes, orforglipron had a mean half-life of 29 to 49 hours at Week 12.

    Peptide
    Orforglipron
    Outcome
    Not applicableHalf-life at week 12
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oral · 12 weeksAs given in this study (human).

    Measurements

    Mean half-life
    29 to 49 hours
    Week 12

    Source sentences

    Summary
    At Week 12, mean t1/2 ranged from 29 to 49 hours.
    2 context sentences
    Summary · context
    Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 weeks.
    Summary · context
    Eligible participants with T2D were aged 18 to 70 years and had glycated haemoglobin (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.